CA2156752C - Multipurpose reagent system for rapid lysis of whole blood samples - Google Patents

Multipurpose reagent system for rapid lysis of whole blood samples

Info

Publication number
CA2156752C
CA2156752C CA002156752A CA2156752A CA2156752C CA 2156752 C CA2156752 C CA 2156752C CA 002156752 A CA002156752 A CA 002156752A CA 2156752 A CA2156752 A CA 2156752A CA 2156752 C CA2156752 C CA 2156752C
Authority
CA
Canada
Prior art keywords
reagent system
recited
multipurpose reagent
multipurpose
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002156752A
Other languages
French (fr)
Other versions
CA2156752A1 (en
Inventor
Young Ran Kim
Joanna Kantor
James E. Gill
Sue E. Luptovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2156752A1 publication Critical patent/CA2156752A1/en
Application granted granted Critical
Publication of CA2156752C publication Critical patent/CA2156752C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G01N2015/1477—Multiparameters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Abstract

A multipurpose reagent system for rapid analysis of a whole blood sample allowing the determination of at least five classes of peripheral white blood cells, nucleated red blood cells, and lymphocyte immunophenotyping on automated hematology instrumentation.
The multipurpose reagent system lyses red cells rapidly, while it concurrently fixes white cells and preserves surface antigens on lymphocytes.
The multipurpose reagent system comprises from about 3 to 7 grams per liter of a non-quaternary ammonium salt, from about 0.04 to about 0.10 percent by volume of an aliphatic aldehyde with one to four carbons, from about 10 mM to about 20 mM of a non-phosphate buffer which is inert to the aliphatic aldehyde, and a sufficient amount of water to give a pH between 55 and 75 and an osmolality of between about 160 to about 310 mOsm per liter.

Description

WO94/18~ PCT~S94/0~06 ~ 21567~2 M~LTIP~RPOSE ~GFNT ~r~ OR
RAPID LYSIS O~ W~OLE BLOOD SAMPLES

BACKGROUND
.

This invention relates to a multipurpose reagent system and a method for a rapid analysis of whole blood samples. More particularly, the present invention relates to a multipurpose reagent system capable of rapidly lysing red cells and concurrently fixing white cells, useful for performing white cell differential analyses and quantitative analyses of nucleated red blood cells or lymphocyte subclassification using ;mmllnophenotyping techniques on an automated clinical hematology analyzer or flow cytometer.

The peripheral blood of a normal subject contains red blood cells, also known as erythrocytes, and five major classes of mature white cells, also known as leukocytes. There are at least five classes of leukocytes, known as neutrophils, eosinophils, monocytes, lymphocytes and basophils. Each type of mature blood cell performs specialized functions necessary in maint~;n;ng the homeostasis of the host. The concentration of each class of peripheral blood cells is tightly regulated and monitored by a _ WO94/188~ PCT~S94/0~0 2~S~ ~ 2 -2-dynamic process involving a variety of factors present in the microenvironment of the bone marrow.
Under certain disease conditions, the bone marrow may release either an increased or decreased number of certain classes of white cells. In other ~onditions, all regulation of the number of peripheral blood cells released from the bone marrow is perturbed and an uncontrolled num.ber of immature white or red cells are released to the peripheral blood.

Therefore, monitoring the concentration of the five normal classes of leukocytes and identifying the presence of immature erythrocytes and leukocytes in the peripheral blood is an important diagnostic tool for physicians. Typically, these functions have been performed by doing white cell differential counts, whereby the relative proportions of the five normal classes of leukocytes and any abnormal cells are determined microscopically. The m~nn~l procedure is very time consuming, subjective and labor intensive.

Recently, automated processes and automated flow system apparatuses have been developed to ease the burden of white cell differential analysis.
Several of these systems are described in U.S.
Patent numbers 4,099,917; 4,617,275; 4,521,518; and 4,801,549. Some of these systems are based on cytochemical procedures to specifically identify individual cell types; some of these systems differentiate three leukocyte types by electronic impedance measurements of cell volume; and other procedures utilize a com.bination of opticàl and WO94/1~ 21~ 2 PCT~S94/0~06 electronic impedance measurements to differentiate the five classes of peripheral white blood cells.

Recent advances in cellular immunology and flow cytometry are being utilized to identify and quantify lymphocyte subclasses such as helper T
cells. Lymphocyte subclassification has become an important diagnostic tool, particularly in view of the growing AIDS epidemic. Conventional lymphocyte subclassification involves the following steps:
(1) The separation of lymphocytes from other peripheral blood cells by density gradient centrifugation; (2) the reaction of the lymphocytes with fluorochrome-labeled monoclonal antibodies directed to specific lymphocyte surface antigens;
and (3) the analysis of lymphocyte-antibody reaction products using flow cytometry. Currently, a great deal of effort is being directed towards the development of whole blood methods that bypass the need for density gradient centrifugation.
Recently developed whole blood methods for lymphocyte subclassification comprises lysing the red cells, removing red cell ghosts and cell debris by centrifugation, and preserving the morphology of the rem~;n;ng white cells by suspending the white cells in an isotonic saline solution cont~;n;ng appropriate fixatives. Although these methodologies avoid the need for density gradient centrifugation, they are still incompatible with available automated clinical hematologic analyzers since they still require a centrifugat-ion step.

Generally speaking, the reagent systems available for use during the analysis of nucleated red blood cells (NRBC) are as yet unable to allow WO94/18828 PCT~S94/01306 2~ 4- f~

~or the differentiation and counting of NRBC
signals from red cell stroma or large platelets and only allow the instrument to flag possible NRBC
signals.

It is im~erative in leukocy~t~e anal~ses that all of the red blood cells be completely lysed.
Since red cells outnumber white cells by about 700 to 1, even Gne percent of unlysed red cells may distort white cell counts. Some reagents used to lyse red cells require too lengthy an incubation period to be practical in an automated clinical analyzer. For example, the Tris buffered ammonium chloride solution recommen~ed by K.A. Murihead in Clinical Cytometry, Ann. N.Y. Acd. Sci., vol. 468, pp. 113-127 (1986) takes 5 to 10 minutes to lyse red cells, which is too impractical for automation.

Furthermore, incomplete hemolysis with certain lytic reagents can result in red cell stroma that retain sufficient hemoglobin to generate high background counts in automated clinical electro-optical systems. Therefore, the white cells to be analyzed must first be removed from the red cell stroma by centri~ugation, a procedure that is a limiting factor when adapting a reagent system for automation.

Other reagent systems, such as those described in U.S. Patent numbers 4,902,613 and 4,654,312, - that are used to lyse red cells, contain high refractive index solvents. A cell suspending medium which has a high refractive index has two disadvantages: (1) The refractive index may be too high for a common flow cell saline sheath; and W094/18~ 21~ 6 7 ~ 2 PCT~S94/0~06 (2) the high refractive index of the suspending medium may mask signals from æmall cellular components such as small lymphocytes and cytoplasm-lysed nucleated red cells. Thus, before the cells can be analyzed in a flow cell, the cells mustibe~removed~ from the high refractive index medium by centrifugation and resuspended in an isotonic solution. Such mAnl~l procedures are not desirable or adaptable for use on a fully automated clinical analyzer.

In addition, lytic reagents, such as those described in U.S. Patent number 5,155,044, are too hypotonic and/or acidic. Such lysing reagents re~uire the rapid "follow-up" addition of a high salt solution and/or alkaline salt solution to preserve the white cell morphology for analysis.
Similarly, lytic reagents, such as those described in U.S. Patent number 4,751,179, will not only lyse red cells but will also lyse white cells, unless a separate fixative is added at the appropriate time and concentration to prevent white cell lysis.
These reagents introduce the potential of white cell damage, particularly in abnormal blood samples cont~; n; ng fragile white cells (such as in blood samples from patients with chronic lymphocytic leukemia [CCL]).

Furthermore, reagent systems, such as those described in U.S. Patent numbers 4,099,917, 4,801,549, and 4,978,624, require incubations at high temperatures, e.g. over 50C, to completely lyse the red cells. Temperatures over 450C will, generally, begin to denature most cell surface antigens and cause hemoglobin clumping in the WO94/188~ PCT~S94/0~06 ~1~ 67 ~ ~ -6-process. Although these systems may be used to perform differential analyses of white cells, they destroy the méans for differentiating subpopulations of lymphocytes and cannot be used for ;mmllnophenotypic lymphocyte classification.

Many of the currently used reagent systems re~uire the cytochemical st~;n;ng of fixed white cells before they are subjected to differential analysis. These systems require the timed addition of multiple reagents and incubation periods and are generally not adaptable for the quantitation of nucleated red cells or for ;mmllnophenotypic lymphocyte classification. Furthermore, each step of reagent addition or other manipulation of a blood sample decreases the precision of the final counts obtained from that sample.

Based on the foregoing, a need has arisen for a multipurpose reagent system which can lyse red cells rapidly and completely, while concurrently preserving white cell morphology and lymphocyte cell surface antigens.

SUr~ARY

The problems discussed above have been solved in the present invention.

Accordingly, an object of the present invention is to provide a multipurpose reagent system, or blood diluent, that will lyse red cells rapidly and completely, while concurrently preserving white cell morphology and lymphocyte cell surface antigens for the automated ~094/18828 21 ~ ~ 7 S ~ PCT~S94/0~06 electro-optical analyses of peripheral whole blood cells.

Another object of the present invention is to provide a multipurpose reagent system that permits the~ rapid different~iation of white cells on~ an automated clinical hematologic analyzer.

Still another object of the present invention is to provide a multipurpose reagent system which permits the identification and quantitation of nucleated red blood cells (NRBCs) on an automated clinical hematologic analyzer.

Yet another object of the present invention is to provide a multipurpose reagent system that eliminates the necessity of centrifuging lymphocyte-antibody reaction products prior to the ~nllm~ration of fluorochrome conjugated antibody bound lymphocyte subclasses on an automated clinical flow cytometer.

The multipurpose reagent system of the present invention is comprised of a non-quaternary ~mmQ~;um salt, an aliphatic aldehyde having one to four carbons, a non-phosphate buffer substantially inert to the aliphatic aldehyde, and water to give an effective pH of between about 5.5 and about 7.5 and an osmolarity of between about 160 to about 310 mOsm/L (milliosmols per liter). Various optional reagents for the present invention include a surface active agent such as saponin, an anticoagulant, an alkali salt of bicarbonate, a nuclear stain, or an antibody directed against specific cell surface antigens.

WO 94/18828 PCT/US94/0L~06~
1.
2~6~ ~2 -8-One method of the present invention comprises preparing a multipurpose reagent system, mixing the multipurpose reagent system with a whole blood sample, incubating the reagent system-blood mixture for at least 10 seconds, and analyzing the blood ~ample on an~automated hematology an~alyzer.

One feature and technical advantage of the present invention is that the disclosed multipurpose reagent system can rapidly and completely lyse red blood cells while concurrently preserving white cell morphology, while, eliminating the need for the addition of a second reagent or fixati~e. The disclosed process of red cell lysis can take place in less than 20 seconds.

Another feature and technical advantage of the present invention is that the disclosed multipurpoæe reagent system fixes white cells ade~uately and will not lyse fragile lymphocytes such as CLL lymphocytes. Further, the multipurpose reagent system has been shown to stabilize white cells exposed to the reagent over extended periods of time.

Still another feature and technical advantage of the present invention is that the disclosed multipurpose reagent system has a refractive index similar to that of isotonic saline, used in other hematologic measurements.

Another feature and technical advantage of the present invention is that the lysing power of the disclosed multipurpose reagent system is potent enough to completely and rapidly lyse red cells in WO94/18828 ~1~ 8 7 ~ 2 PCT~S94/0~06 as low as a 16-fold diluted whole blood sample, thus retaining sufficient white cell density to allow accurate and rapid cell analysis. This allows for automated analysis in a multi-parameter clinical instrument.

Still another feature and technical advantage of the present invention is that the disclosed multipurpose reagent system preserves lymphocyte cell surface antigens, for example, CD3, CD4, CD8, and CD19.

Yet another feature and technical advantage of the present invention is that the disclosed method lyses red blood cells so thoroughly that signals from red cell ghosts are sufficiently small to be clearly separated from those of lymphocytes without washing or otherwise removing the red cell stroma while still providing improved subpopulation separation.

Yet another feature and technical advantage of the present invention is that the disclosed method of peripheral blood analysis bypasses the need for either conventional or density gradient centrifugation steps.

Still yet another feature and technical advantage of the present invention is that the disclosed method permits the quantification of nucleated red blood cells on a clinical flow cytometer.

A further feature and technical advantage of the present invention is that the disclosed WO94/18828 PCT~S94/0~06 ~ 6'~ S2 -10- ~

multipurpose reagent system enables a rapid, one-reagent, one-tube, automated differential analysis of peripheral white blood cells.

An additional feature and technical advantage 5" ~f the P~xesent inventio~ i& that method allows for~-a rapid differential analysis of lymphocyte subclasses on an automated flow cytometer.

These and further features and advantages of the invention will be apparent from the following description of the preferred embodiments therecf.

WO94/18~8 PCT~S94/0~06 ~ 2153~75~

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present in~ention, and the advantages thereof, reference is now made to the following descriptions 5 . taken in conjunction with the accompallyi~
drawings, in which:

FIGURE 1 shows the white cell distribution of a normal blood sample processed as described in Example 1. The prepared cell suspension was run directly through a CD3500~ analyzer optical system bypassing the system's hydraulics;

FIGURE 2 shows the white cell distribution of a normal blood sample processed as described in Example 12. The processed cell suspension was run directly through a CD3500~ analyzer optical system bypassing the system's hydraulics. Each cluster represents a white cell subpopulation as labeled;

FIGURE 3a shows a FACScan~ display printout of a normal blood sample, processed as described in Example 5 with a nuclear stain but without chicken erythrocyte nuclei (CEN);

FIGURE 3b shows a FACScan~ display printout of a normal blood sample, supplemented with chicken erythrocyte nuclei, that was processed as described in Example 5 with a nuclear stain. An FL3 stained CEN population appears at the upper left hand corner;

WO94/18828 PCT~S94/0~06 FIGURES 4a, 4b, 4c and 4d show FACScan~
display printouts of a normal blood sample processed as described in Examples 2, 3 and 4.

FIGURES 5b, 5d, 5f and 5h show FACScan~
5- disp~ rin~outs o-f~ ~ n~rma~ ~oo~ sample -processed as described in Examples 2, 3 and 4 for ;mml~no-phenotyping and FIGURES 5a, 5c, 5e and 5g show FACScan~ display printouts of the same sample prepared in the same way but lysed with Becton Dickinson's FacsLyse~.

-WO~41188~ 215 6 7 ~ 2 PCT~S94/0~06 D~TAILED DESCRIPTIO~

Broadly, the present invention relates to a multipurpose reagent system, or blood diluent, suitable for the rapid analysis of nucleated 5- p~riph~r~l blood cel 1B ~ The multipurpose reagent system can completely and rapidly lyse red blood cells, while concurrently preserving white cell morphology and the antigenicity of lymphocyte surface antigens.

One aspect of the present invention is the multipurpose reagent system, comprising of from about 3 to about 7 grams per liter of a non-quaternary ~mmn~;um salt, from about 0.04 to about 0.1~ by weight volume (i.e., grams per 100 ml) of an aliphatic aldehyde with one to four carbons, from about 10 to about 20 mM of a non-phosphate buffer which is substantially inert to the aliphatic aldehyde, and water. The pH of the reagent system is within a pH range of about 5.5 to about 7.5 and the osmolality of the reagent system is between about 160 to 310 mOsm/L. The refractive index of the reagent system can be similar to that of saline and would be within the range of about 1.333 to about 1.336. The non-phosphate buffer which does not contain any primary amino group is inert to the aliphatic aldehyde.
Thus, generally, the non-phosphate buffer should not contain a primary amino group.

A preferred embodiment of the present in~ention utilizes a multipurpose reagent system comprised of about 95 mM ~mmon;um chloride (5g/1), about 0.075~ by volume of formaldehyde, from about _ -WO94/188~ PCT~S94/0~06 p~61~ -14-10 mM tc about 20 mM acetate buffer, about 10 mM
potassium bicarbonate, and about 0.01~ by weight volume (i.e., grams per 100 ml) of saponin. The pH
of the reagent system is adjusted to a range of from about 6.2 to about 6.5 and the osmolality of the reagent system is from about 215-to~about 270 mOsm/L.

Osmolality is defined as the number of dissolved particles in a,unit volume of an aqueous solution. Osmolarity is defined as the number of dissolved particles in a unit weight of water solution. As a practical matter, osmolality and, osmolarity have numerical values which are very close in the ranges involved in the present invention. A solution that has 1/1000 of an osmol dissolved per kilogram has a concentration of 1 milliosmos ("mOs") per kilogram. An osmol is the number of particles in 1 gram molecular weight of undissociated solute. Tonicity is a measure of the osmotic pressure of a solution relative to the osmotic pressure of the blood fluids. A hypotonic solution is a solution of lower osmotic pressure of tonicity than that of blood. The osmolality of a hypotonic solution is usually in the range of about 80-250 mOs/l. An isotonic solution has the same tonicity as blood. Here, the osmolality usually ranges from about 280 to about 310 mOs/l. A
hypertonic solution is a solution of greater tonicity than blood which normally has an osmolality range of about 310-440 mOs/l. Water has the osmolality of about 10-20 mOs/l.

The present invention also pertains to the use of the multipurpose reagent system in the automated -WO94/188~ 21~ 6 7 ~ ~ PCT~S94/0~06 determination of differential white cell counts, nucleated red blood cells, and lymphocyte ;mmllnophenotyping. The method for the rapid analysis of nucleated peripheral whole blood cells includes the following steps: m; ~; ng the mul,tipurpose reagent. system of the present invention with an anticoagulated whole blood sample (whereby the blood is diluted 16 to 100 fold), incubating the diluent-blood mixture at temperatures from about 25C to 46C for at least 10 seconds, and analyzing the nucleated peripheral blood cells with automated hematology instrumentation.

The method using the multipurpose reagent system of the present invention in the differential analysis of peripheral white blood cells is a rapid, one-reagent method of concurrently lysing red blood cells and fixing white blood cells, wherein the white cells maintain their light scattering characteristics. Example 1 illustrates the application of a preferred embodiment of the disclosed multipurpose reagent system in a rapid process for white cell differential analysis.
FIGURE 1 shows the differential analysis of white cells in a normal blood sample (processed as described in Example 1) by light scattering. In general, the cells flow through an optical view chamber where a photoelectric measuring process records the light absorbed or type of light scattered by each cell at selected angles.
Electronic signals, from scattered light collected at different angles, are plotted as two ~;m~n~ional dot plots as illustrated in FIGURE 1. Granulocytes are identified first on the cytogram, 10 deg vs 90 WO94118$~ PCT~S94/0~06 ( ~56~ 16-deg scatter plot, by drawing the threshold between the granulocytes and the rest of the white cell population as shown in FIGURE lc. Eosinophils are identified next on the ORTHOGONAL vs DEPOL cytogram as shown in FIGURE lb. Then, monocytes and lymphocytes~ are identified on~ the SI~ZE vs COMPLEXITY cytogram (FIGURE la) along the Y axis because monocytes are larger than lymphocytes. The signals that fall between lymphocytes and granulocytes along the X axis (COMPLEXITY) and which are lower than that of monocytes along the Y
axis that do not belong to any of the populations already identified ~neutrophils and eosinophils) are basophils, as labeled (FIGURE la).

A first ingredient of the multipurpose reagent system is a non-quaternary ~mmon;um salt.
Preferably, neither di- nor tri-~mmon;um salts should be used. A variety of mono-~mmon;um salts, particularly the halogenated salts, can be used from about three to about seven grams per liter, and preferably at 5 grams per liter. Examples of such non-quaternary ammonium salts include NH~X, where X is a halogen. Preferably, such a non-quaternary ~mmon;um salt is NH4Cl.

A second ingredient of the multipurpose reagent system is a short-chain aliphatic aldehyde.
Preferably, such aliphatic aldehydes have from one to four carbons. Exemplary aldehydes include formaldehyde and the polymer, paraformaldehyde. In proper ratios and concentrations, the aldehyde, in conjunction with the non-quaternary mono-~mmo~;um salt, and the buffer, will rapidly and completely lyse the red blood cells. In addition, the aldehyde WO94tl8~8 21~ 8 7 ~ ~ PCT~S94/0~06 will fix white blood cells and preserve their membrane integrity. Formaldehyde, or comparable aldehyde, will be present in the present invention in amounts from about 0.04~ to about 0.10~ by volume, and preferably from about 0.08~ to about 0.1~ by vQlume.

A third ingredient of the multipurpose reagent system is a non-phosphate buffer that is substantially inert to the aldehyde component of the reagent system. Thus, the buffer must not contain a primary amino group. The bufer should also have an effective buffering capacity between pH of about 5.5 and about 7.5. Examples of effective organic buffers are acetate buffer, succinate buffer, maleate buffer, and citrate buffer. Examples of effective biologic buffers are 2-(N-morpholine)ethane sulfonic acid (MES) buffer, 3-(N-morpholine)propane sulfonic acid (MOPS) buffer, and N-(2-hydroxyethyl)piperazine-N'-(2-ethane sulfonic acid) (HEPES) buffer. An acetate,or other suitable buffer, will be present in the present invention in amounts from about 10 mM to about 20 mM concentrations, and preferably at about 20 mM concentr-~tion. Embodiments of the present invention using MES buffer, MOPS buffer, and HEPES
buffer are described in Examples 6, 7, and 8, respectively.

An optional component of the multipurpose blood diluent is a surface active reagent. The preferred surface active agent is saponin, a plant extract that is available in a commercial grade powder isolated from quillaja tree bark as well as other sources. Although the chemical purity of WO94/18828 PCT~S94/01306 ,~

6~
commercial saponin varies from lot to lot, it is more selective towards red cells than are the quaternary ~mmon; um salts. Saponin, or other surface active reagent, is present in the present invention in amounts from about 10 to about 200 mg/L, and preferably at about 100 mg/L. 5ap~nin, in concert with the other ingredients of the multipurpose reagent system completely lyses the red blood cells present in whole blood. The erythrocyte fraction (i.e. red blood cells) of normal blood samples will be lysed within about 20 seconds at ambient temperatures. However, hard-to-lyse blood samples (such as blood samples from babies, kidney dialysis patients, multiple myloma patients, diabetics, or patients with uremia) require incubating the blood with the reagent system at temperatures of about 38C to about 43C for up to 20 seconds for complete erythrocyte lysis. Incubation of blood samples with the multipurpose reagent system, even at these slightly elevated temperatures, effectively preserves white cell membrane integrity and retains the antigenicity of lymphocyte surface antigens.
In contrast, if saponin is used by itself to lyse the red cells, it must be used at a concentration 10 to 20 times higher than those used in the present invention. Such concentrations are extremely damaging to the integrity of the white cells and require a rapid qu~nch;ng of the lytic activity of the reagent to preserve white cell morphology. An advantage of the present invention is that the combined constituents of the multipurpose reagent system serve to gently fix the white cells at the same time that the red cells are being lysed. Therefore, white cell integrity is WO94/18~ 7 5 ~ PCT~S94/0~06 preserved even at relatively long incubation periods. In fact even fragile white cells, such as those seen in chronic lymphocytic leukemia, are stabilized in the multipurpose reagent system of the present invention for incubation periods of up to 2a minutes.

FIGURE 2 shows the distribution of white cells in a normal blood sample processed as described in Example 12 and run on the CD3500~ analyzer (Abbott Diagnostic, Mountain View, CA) system directly through its optical system but bypassing the system hydraulics. Granulocytes are identified first from the rest of the white cell populations, as labeled, on the 10 deg vs 90 deg scatter plot, by setting the threshold as shown in FIGURE 2c. Eosinophils are identified next on the ORTHOGONAL vs DEPOL
scatter plot (FIGURE 2b), as labeled, by setting the threshold between eosinophils and neutrophils as shown in FIGURE lb. Then, monocytes and lymphocytes are identified on the COMPLEXITY vs SIZE scatter plot, as labeled (FIGURE 2a). The signals that fall between lymphocytes and granulocytes along the X axis (COMPLEXITY) and which are lower than that of monocytes along the Y
axis that do not belong to any of the populations already identified (neutrophils and eosinophils) are basophils, as labeled (FIGURE 2a).

A preferred but optional ingredient of the multipurpose reagent system according to the present invention is an alkali salt, preferably a monovalent alkali salt of bicarbonate. Although a monovalent alkali salt of bicarbonate is not an essential component of the diluent, it may be added WO94tl88~ PCT~S94101306 ,~

to the diluent to raise its osmolality without reducing the red cell lysability of the reagent system. Many other compounds, such as sodium chloride, potassium chloride or phosphate buffer, will ~;m;n; sh the lysability of the reagent system i~-t~ey are~used to increase the osmo-lality-of the reagent system. Exemplary monovalent alkali salts of bicarbonate are potassium bicarbonate, sodium bicarbonate, or lithium bicarbonate. Potassium bicarbonate, or other alkali bicarbonate salt, can be present in the present invention in amounts from about 0.005~ to about 0.015~ weight/volume (i.e.
milligrams per lO0 ml), and preferably at about O.Ol~ weight/volume.

Another optional ingredient of the multipurpose reagent system according to the present invention is a platelet anti-clumping agent. For example, an ethylenediaminetetraacetate (EDTA) salt can be added to the reagent system to prevent platelet aggregation in the sample/reagent mixture. Tetrasodium EDTA, or other EDTA salts, will be present in the present invention in amounts from about 20 to about 200 mgs per liter, and preferably at lO0 mgs per liter.

Another embodiment of the present invention allows for the quantitative analysis of nucleated red cells on automated hematology analyzers. In order to analyze the percentage of nucleated red cells present in a whole blood sample, a nuclear stain, e.g., ethidium homodimer, is added to the multipurpose reagent system before it is added to the blood sample. In this embodiment, the nuclear stain is added to the reagent system in an amount WO94/1$~ PCT~S94/0~06 -21_215~7~

from between about 0.05 mg~ to about 0.15 mg~
weight/volume (i.e., milligrams per 100 ml), and preferably at 0.1 mg~ weight/volume. The reagent system completely lyses the red cells while simultaneously preserving the integrity of white cel~l membranes. In the multipurpose r~age~t system, the added nuclear stain reacts with the exposed nuclei of immature red cells, yet it is impenetrable to intact white cells. Since the only nuclear material available to interact with the nuclear stain is that from the nucleated red blood cells, the stained nuclear material is proportional to the nucleated erythrocyte fraction of the blood sample and can be quantitated on an automated electro-optical analyzer. This one-rea~ent process of the present invention allows one to rapidly distinguish the different leukocyte populations from nucleated erythrocytes, and is particularly useful for certain veterinary applications.

FIGURES 3a and 3b show a FACScan~ display of a normal blood sample with chicken erythrocyte nuclei (CEN) processed as described in Example 5. The sample shown in FIGURE 3a was processed with a nuclear stain but without CEN and the sample shown in FIGURE 3b was processed in the presence of both a nuclear stain and CEN. The two ~;m~n~ional dot plots on the left have plotted side scatter (SSC) versus forward scatter (FSC). The two ~;m~n~ional dot plots on the right have SSC signals plotted versus red fluorescence (FL3) from all the cells in the sample. Note the appearance of a FL3 stained CEN population in FIGURE 3b at the upper left corner.

WO94/18~ PCT~S94/01306 ~6~5~ -22-A further embodiment of the present invention allows for the quantitative analysis of lymphocyte subpopulations. Lymphocyte subclassification is achieved by mixing fluorochrome-conjugated monoclonal antibodies, directed to specific lymphocyte surface~ antigens, with whole blood samples before adding the multipurpose reagent system, or blood diluent. The concentration of labeled antibody fractions added to a blood sample will depend upon the individual antibody preparation, but is co~mo~ly about one-half to one-tenth of the volume of the blood for commercial antibody preparations. After the reagent system is added and the red cells are lysed, the lymphocyte-antibody reaction products can be analyzed on an automated flow cytometric system.
The disclosed reagent system does not "quench"
fluorescent markers, such as fluorescein isothiocyanate (FITC) or phycoerytherin (PE), which are fre~uently used to fluorochrome-label antibodies. Lymphocyte subclassification has become increasingly important as a diagnostic tool with the advent of the AIDS epidemic. The ability to identify surface markers on blood cell populations is likely to become increasingly important over the years as scienti~ts increase their knowledge of surface components and characteristics of subpopulations of lymphocytes and other white cell fractions such as monocytes and neutrophils.

FIGURES 4a, 4b, 4c and 4d show a FACScan~
displays of a normal blood sample processed as described in Examples 2, 3 and 4. FIGURE 4a was processed withGut the addition of any antibody as WO94/18$~ PCT~S94/0~06 .

-23- 215 67~ 2 a negative control of the donor sample; FIGURE 4b was processed as described in Example 4 to identify pan B cells (CDl9+ lymphocytes) and pan T cells (CD3+ lymphocytes). The lymphocyte population was gated first on the Forward Scatter (FSC) vs Side Scatter (SSC) ;plot and ~-reanalyzed in the Green Fluorescence (FLl) vs Orange Fluorescence (FL2) ch~nnPls. As can be seen in FIGURES 4a, 4b, 4c and 4d, unlabeled lymphocytes were all in the lower left quadrant, while the CD3-FITC antibody labeled Pan T cells moved out to the lower right quadrant and the CDl9-PE labeled Pan B cells moved up to the upper left quadrant. FIGURE 4c sample was processed as described in Example 2 to identify Helper T cells (CD4+ lymphocytes). Helper T cells are a subpopulation of T lymphocytes and have both CD3 and CD4 antigens on the cell surface and therefore they moved out to the right because of the FITC label on the anti-CD3 antibody and moved up to the upper right quadrant because of the PE
label on the anti-CD4 antibody. FIGURE 4d sample was processed as described in Example 3 to identify suppressor T cells (CD8+ lymphocytes). Suppressor T cells are also a subpopulation of T lymphocytes and have both CD3 and CD8 antigens. Therefore the cells were labeled with both antibody and fell into the upper right quadrant.

FIGURES 5b, 5d, 5f and 5h represent FACScan~
display printouts of a normal blood sample processed as described in Examples 2, 3 and 4.
FIGURES 5a, 5c, 5e and 5g represent the same sample processed as described in the same examples above, except that the red cells were lysed with a commercial lysing solution, Becton Dickinson's WO94/188~ PCT~S94/01306 ~S ~ 24-Facs~yse~ as described in Example 11. Columns 1 and 3 are FSC vs SSC cytograms and columns 2 and 4 are FL1 vs FL2 two ~;m~n~ional dot plots of the gated lymphocytes. The same FSC, SSC, FLl and FL2 gains were used for the analysis of both samples for ~omp~rison. -As can be seen in the FSC vs SSC cytograms,the right column cytograms show well defined clusters of neutrophils, eosinophils, monocytes and lymphocytes, which are all well separated from noise (the signals mostly from red cell stroma), indicating that the white cells were well preserved in the multi-purpose blood diluent. This allows more accurate lymphocyte gating. In comparison, the cell clusters of the left column cytograms are less well defined. The resolution of each cell cluster is less clear and the signals of the granulocytes are much lower than that of the right column, suggesting an alteration in the refractive index of these cells which may have resulted from the leakage of some protein components. The quality of the FLl vs FL2 two ~;m~n~ional dot plots of the gated lymphocytes of the last column is essentially equivalent to that of the corresponding dot plots of the second column whose red cells were lysed with FacsLyse~.

FIGURE 5a is a negative control of a normal blood, processed as described in Example 2 but not reacted with any antibody, lysed with FacsLyse~;
FIGURE 5b is also a negative control of the same sample but red cells were lysed with the multipurpose diluent of one embodiment of the present invention. FIGURES 5c, e and g represent WO94/18~ PCT~S94/0~06 21~752 the same sample processed as described in Examples 2, 3 and 4 but red cells were lysed with Facs~yse~
as described in Example 11. FIGURES 5d, f and h are the same sample processed as described in Examples 2, 3 and 4 in which red cells were lysed with the multipurpose diluent of onerembodiment of the.present invention.

The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.

~ll~ BLOOD CELL DIFFERENTIAL ANALYSIS
-Fifty microliters of an EDTA-anti-coagulated normal blood sample was mixed with 1 ml of the multipurpose reagent system prewarmed at 40C, mixed and incubated at room temperature for 16 seconds. me reagent system contained 0.5 weight/volume ammonium chloride, 0.08~
weight/volume of formaldehyde, 0.01~ weight/volume of saponin, 0.1~ weight/volume of potassium bicarbonate, and 20 mM of acetate buffer. The reagent s~stem had a pH of about 6.2 and an osmolality of 267 mOsm/L. This mixture was incubated at 38+2C for 16 seconds and run on the CD3500~ system directly through the optical system bypassing the system hydraulics. The cytograms of the sample are presented in FIGURE 1.

W094/188~ PCT~S94/0~06 LYMPHOCYTE IMMUNOPHENOTYPING

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with 10 microliters of monoclonal antibody æolution cont~;n;ng anti-CD3-FITC and anti-CD4-PE in a test tube.
The mixture was incubated at room temperature for 15 minutes before adding 1.0 milliliter of the multipurpose reagent system of the present invention containing 0.5~ weight/volume of ~mm~;um chloride, 0.02~ of weight/volume of tetra sodium EDTA, 0.1~ of volume of formaldehyde, 0.0075 weight/volume of saponin, 0.01~ weight/volume of potassium bicarbonate, and 20 mM acetate buffer.
The reagent system had a pH of about 6.2 and an osmolality of 270 mOsm per liter, while the reagent system-blood solution had a pH around 7Ø
The reagent system-blood solution was incubated from 20 seconds to 10 minutes at room temperature. This variation in acceptable incubation time allowed for the analysis of multiple samples.
The percent of CD3+ and CD4+ lymphocyte subpopulations was determined on the FACScan~ flow cytometer as illustrated in FIGURE 4a.

LYMPHOCYTE IMMUNOPHENOTYP`ING

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with 10 microliters of monoclonal antibody solution cont~;ning anti-CD3-FITC and anti-CD8-PE in a test tube.

WO94/18~ 2 1 5 6 ~ ~ 2 PCT~S94/0~06 The mixture was incubated at room temperature for 15 minutes before adding 1.0 milliliter of the multipurpose reagent system of the present invention containing 0.5~ weight/volume of ~mmon;um chloride, 0.02~ weight/volume of tetra sodium EDTA, ~ of volum~ of formaldehyde, 0.0075 weight/volume of saponin, 0.01~ weight/volume of potassium bicarbonate, and 20 mM acetate buffer.
The reagent system, described in EXAMPLE 1, had a pH of about 6.2 and an osmolality of 270 mOsm per liter.
The whole blood-reagent system solution could be incubated anywhere from 20 seconds to 10 minutes at room temperature, which allowed for the analysis of multiple samples.
The percent of CD3+ and CD8+ lymphocyte subpopulations were determined using the FACScan~
flow cytometer.

LYMPHOCYTE IMMUNOPHENOTYPING

Fifty microliters of EDTA-anti-coagulated whole blood was m; ~ with 10 microliters of monoclonal antibody solution cont~;ning anti-CD3-FITC and anti-CD19-PE in a test tube.
The mixture was incubated at room temperature for 15 minutes before adding 1.0 milliliter of a multipurpose reagent system of the present invention cont~;n;ng 0.5~ weight/volume of ~mmon;um chloride, 0.02~ weight/volume of tetra sodium EDTA, 0.1~ volume of formaldehyde, 0.0075~ weight/volume of saponin, 0.01~ weight/volume of potassium bicarbonate, and 20 mM acetate buffer. The multi-purpose reagent system, as described in EXAMPLE 1, WO94/18828 PCT~S9410~06_ ~6~ 28-had a pH of about 6.2, and an osmolality of 270 mOsm per liter.
The whole blood-reagent system solution could be incubated from 20 seconds to 10 minutes at room temperature. This variation in incubation time permits the~analysis of m~ltiple samples The percent of CD3+ and CD19~ lymphocyte subpopulations were determined using a FACScan~
flow cytometer as illustrated in FIGURE 4b.

NUCLEATED RED BLOOD CELL DETERMINATION

Fifty microliters of an EDTA-anti-coagulated whole blood samples with and without chic~en nuclei ~ere mixed with 950 microliters of the multipurpose reagent system of the present invention containing 0.1 mg~ weight/volume of a nuclear stain, 0.5 weight/volume of ~mmo~;um chloride, 0.075~ of volume of formaldehyde, 0.01~ weight/volume of saponin, 0.01~ weight/volume of potassium bicarbonate, and 20 mM acetate buffer. The multipurpose reagent system had a pH of about 6.0 and an osmolality of 270 mOsm per liter.
The whole blood-reagent system solution was incubated at 38+2C for 20 seconds.
The percentage of nucleated red blood cells in the whole blood sample was determined on a FACScan~
flow cytometer as illustrated in FIGURES 3a and 3b.

WHITE BLOOD CELL ~IF~FERENTIAL.ANAL~SIS

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with 950 microliters of the WO~4/188~ PCT~S94/0~06 -29- 2 ~ a G 75 ~

multipurpose reagent system of the present invention containing 20 mM MES buffer, 0.5~
weight/volume of ~mmon;um fluoride, 0.08~ of volume of formaldehyde, and 0.0l~ weight/volume of saponin. The reagent system had a pH of about 6.2 and an ~smolaliity~of 280 mOs~ per liter.
The whole blood-reagent system solution was incubated at 40C for 20 seconds.
A differential analysis of the white blood cells was performed on an experimental clinical flow cytometer.

W~l'l'~ BLOOD CELL DIFFERENTIAL ANALYSIS

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with l.0 milliliter of the multipurpose reagent system of the present invention cont~;n;ng 20 mM MOPS buffer, 0.5~
weight/volume of ~mmo~;um chloride, 0.l~ of volume of formaldehyde, 0.012~ weight/volume of saponin and 0.0l~ weight/volume of tetrasodium EDTA. The multipurpose reagent system had a pH of about 7.0 and an osmolality of 280 mOsm per liter.
The whole blood-reagent system solution was incubated at 42C for 20 seconds.
A differential analysis of the white blood cells was performed on an experimental clinical flow cytometer.
i WHITE BLOOD CELL DIFFERENTIAL ANALYSIS

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with l.0 milliliter of the WO94/18~ PCT~S94/01306 ~S6~ 30-multipurpose reagent system of the present invention cont~;n;ng 20 mM HEPES buffer, 0.4~
weight/volume of ~mm~n;um fluoride, 0.08~ of volume of formaldehyde, 0.01~ weight/volume of saponin, and 0.1~ weight/volume of potassium bicarbonate.
The reagent system had a pH of about 7.0 and an osmolality of 270 mOsm per liter.
The whole blood-reagent system solution was mixed at 40C for about 20 seconds.
A differential analysis of the white blood cells was performed on an experimental clinical flow cytometer.

DIFFERENTIAL INCUBATION TIMES FOR
WHITE BLOOD CELL DETERMINATIONS

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with 950 microliters of the multipurpose reagent system of the present invention at 38+2C. The reagent system contained 0.5~ weight/volume of ~mmQ~;um chloride, 0.08~ of volume of formaldehyde, 0.01~ weight/volume of saponin, 0.01~ weight/volume of potassium bicarbonate, and 20 mM acetate buffer. The reagent system had a pH of about 6.2 and an osmolality of 267 mOsm per liter.
The mixture was incubated at 38+2C and serial ali~uots of the mixture were removed at 14 seconds, 2 minutes, 4 minutes, 6 minutes, 8 minutes, and 10 minutes.
A five-part differential analysis of the white blood cells was performed on each aliquot on an experimental clinical flow cytometer equipped with an argon-ion laser.

WO94/18$~ 215 6 7 ~ 2 PCT~S94/0~06 VARIATIONS IN INCUBATION TIME AND TEMPERAT~E
FOR WHITE BLOOD CELL DETERMINATIONS

Fifty microliters of EDTA-anti-coagulated whole blood was mixed with 950 microliters~of the multipurpose reagent system of the present invention containing 0.5~ weight/volume of ~mmo~;um chloride, 0.08~ of volume of formaldehyde, 0.01~
weight/volume of saponin, 0.01~ weight/volume of potassium bicarbonate, and 20 mM acetate buffer.
The reagent system had a pH of about 6.2 and an osmolality of 267 mOsm/L.
Aliquots of the resultant mixture were incubated at 36C, 38C, 40C, 42C, 45C, and 46C
respectively for various time intervals up to 10 minutes.
A five-part white cell differential analysis was deter~;ne~ on samples of each aliquot using an automated electrical optical system.

COMPARATIVE STUDIES OF A COMMERCIAL
LYSING SOLUTION AND THE MULTIPURPOSE
REAGENT SYSl~M OF THE PRESENT INVENTION

A commPrcial lysing solution from Becton Dickinson (FacsLyse~) was compared with one embodiment of the multipurpose reagent system of the present invention t~he "Multipurpose Diluent'l) in an ;mmllno-phenotyping experiment The samples were processed as described in Examples 2, 3, and 4 and the results are presented in TABLE 1.

WO 94/18828 PCT/US94/0L~06 .

~r~ 3 2 -In the case the commercial Facs~yse~, the mixture of the test sample and the FacsLyse~ was first incubated in the dark at room temperature for 10 minutes. Afterward, the resulting mixture was centrifuged for 5 minutes at 3000 g. The supernatant was separated and the ceIl button was then washed with 1 ml of phosphate buffered saline.
The cell suspension was again centrifuged for 5 minutes at 3000 g. Afterward, the cell button was resuspended in a phosphate buffered saline containing 1~ by weight of paraformaldehyde. The assay was then performed on a FACScan~.

In contrast to the elaborate and lengthy red cell lysing procedure as described above, in the case of one embodiment of the multipurpose reagent system of the present invention (the "Multipurpose Diluent"), the entire assay procedure was completed in about 20 seconds. No washing step was required.

The comparative data are compiled in TABLE 1.
As can be seen from this TABLE, the results obtained from the procedure using a commercial lysing solution and those obt~; ne~ from the procedure using the multipurpose reagent system of the present invention are essentially equivalent.

WHITE BLOOD CELL DIFFERENTIAL ANALYSIS

Fifty microliters of an EDTA-anti-coagulated normal blood sample was mixed with 1 ml of the multipurpose reagent system prewarmed at 40C, mixed and incubated at room tempèrature for 16 seconds. The reagent system contained 0.5~

WO94/18~ PCT~S94/0~06 ~33~ 21~67~

weight/volume of Ammo~;um chloride, 0.08~ volume of formaldehyde, 0.01~ weight/volume of saponin, 0.1~
weight/volume of potassium bicarbonate, and 10 mM
of acetate buffer. The reagent system had a pH of about 6.2 and an osmolarity of 225 mOsm/L. This mixture was incubated at 38+2C for 16 secondsiand run on the CD3500~ analyzer system directly through the optical system but bypassing the system hydraulics. The cytograms of the sample are presented in FIGURB 2.

Although the present invention and its advantages have been described in detail, it should be appreciated by those ækilled in the art that the conception and the specific embodiments disclosed may be readily utilized as a basis for modifying or designing other systems or reagents for carrying out t~e same purposes of the present invention. It should also be realized by those skilled in the art that such e~uivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims.

WO g4/18828 2~j6~ 34-T~BLE 1. C~RISON OF LYl~OCYTE SIJB lY~G ~ESUL~i CS LYSE ~ MULIIPURPOSE B~D DILUB~T DISCLOSED

Typc of ~b. Dwor l ~ d F.~ t y~
uscd for ~mm~n~ No. pop~ ~ ~iluc~lt CD3FlIC/FD4PE 2Jo.l CD3 CD4+ 1.36 1.?S
CD3+CD4+ 32.66 31.84 CD3~ 3S.14 37.43 CD3^CD3+ 30.84 28.98 CD3~11-C/CD8PE No.1 CD3 CD8+ 3.94 3.S3 CD3+CD8+ 23.S4 27.26 CD3-~D8- 34.19 37.40 CD3 +CD8- 34.61 3S.S2 CD3FlTCICD19PE No.l CD3-CD19+ 24.77 26.41 CD3+F~19+ 1.16 0.~0 CD3-CDl9- 12.S3 10.36 CD3+CD19- 61.S4 63.03 CD3FITC/CD4PE No.2 CD3-CD4 + 2.~9 3.4S
- CD3+CD4+ 4~.66 4S.86 CD3~D~ 24.90 2S.73 CD3+CD4 2S.02 2S.80 CD3FITC/CD8PE No 2 CD3 CD8+ 7.g9 7.8~
CD3+CD8+ 24.S2 24.9S
CD3 CD8- 24.17 23.40 CI~3+CD8+ 43.32 ~3.85 CD3~ C/CDl9PE No.2 CD3 CD19+ 9.83 9.8S
CD3+C~D19+ 0.3S 0.00 CD3-CDl9- 20.94 18.61 CD3+CD19- ~8.88 71.S4

Claims (37)

WHAT IS CLAIMED IS:
1. A multipurpose reagent system suitable for concurrently lysing red cells and fixing white cells from a whole blood sample for the determination of nucleated blood cells, the multipurpose reagent system comprising:
from about 3 to about 7 gm/L of a non-quaternary ammonium salt;
from about 0.04 to about 0.10 percent by volume of a short-chain aliphatic aldehyde;
from about 10 to about 20 mM of a non-phosphate buffer, said non-phosphate buffer being characterized as substantially inert to said aliphatic aldehyde; and water, such that said multipurpose reagent system is maintained at a pH between about 5.5 to about 7.5 and an osmolality between about 160 to about 310 mOsm per liter.
2. The multipurpose reagent system as recited in claim 1 further comprising from about 10 to about 200 mg/L of a surface active agent.
3. The multipurpose reagent system as recited in claim 1, wherein said reagent system has a refractive index of from about 1.333 to about 1.336.
4. The multipurpose reagent system as recited in claim 1, wherein said reagent system has an osmolality of about 200 to about 280 mOsm/L.
5. The multipurpose reagent system as recited in claim 1, wherein said non-quaternary ammonium salt comprises a mono-ammonium salt.
6. The multipurpose reagent system as recited in claim 1; wherein said non-quaternary salt comprises ammonium chloride.
7. The multipurpose reagent system as recited in claim 1, wherein said non-quaternary salt comprises ammonium fluoride.
8. The multipurpose reagent system as recited in claim 1, wherein said short chain aliphatic aldehyde comprises a one to four carbon aliphatic aldehyde.
9. The multipurpose reagent system as recited in claim 1, wherein said short chain aliphatic aldehyde comprises formaldehyde.
10. The multipurpose reagent system as recited in claim 1, wherein said short chain aliphatic aldehyde comprises paraformaldehyde.
11. The multipurpose reagent system as recited in claim 1, wherein said buffer does not contain a primary amino group.
12. The multipurpose reagent system as recited in claim 2, wherein said surface active reagent comprises saponin.
13. The multipurpose reagent system as recited in claim 1, further comprising an alkali salt.
14. The multipurpose reagent system as recited in claim 13, wherein said alkali salt comprises a monovalent alkali salt of bicarbonate.
15. The multipurpose reagent system as recited in claim 1 further comprising a platelet anti-clumping agent.
16. The multipurpose reagent system as recited in claim 15, wherein said platelet anti-clumping agent comprises from about 20 to about 200 mg per liter of an ethylenediaminetetraacetate (EDTA) salt.
17. The multipurpose reagent system as recited in claim 16, wherein said EDTA salt comprises tetrasodium EDTA.
18. The multipurpose reagent system as recited in claim 1, further comprising from about 0.05 mg % to about 0.015 mg % by weight volume of nuclear stain.
19. The multipurpose reagent system as recited in claim 1, further comprising about 0.1 mg % by weight volume of nuclear stain.
20. A multipurpose reagent system suitable for concurrently lysing red cells and fixing white cells from a whole blood sample for the determination of nucleated blood cells, the multipurpose reagent system comprising:
about 5 gm/L of a non-quaternary ammonium salt;
about 0.075 percent by volume of a short-chain aliphatic aldehyde;

from about 10 mM to about 20 mM acetate buffer;
about 100 mg/L of saponin;
about 10 mM potassium bicarbonate; and water, such that said multipurpose reagent system is maintained at a pH range of from about 6.2 to about 6.5 and an osmolality between about 215 and 270 mOsm/L.
21. The multipurpose reagent system as recited in claim 20, wherein said non-quaternary ammonium salt comprises ammonium chloride.
22. The multipurpose reagent system as recited in claim 20, wherein said non-quaternary ammonium salt comprises ammonium fluoride.
23. The multipurpose reagent system as recited in claim 20, wherein said short chain aliphatic aldehyde comprises paraformaldehyde.
24. The multipurpose reagent system as recited in claim 20, wherein said short chain aliphatic aldehyde comprises formaldehyde.
25. The multipurpose reagent system as recited in claim 20, further comprising 0.1 mg % of nuclear stain.
26. The multipurpose reagent system as recited in claim 20, further comprising about 100 mg/L of tetrasodium EDTA.
27. A diagnostic reagent kit useful for the determination of immunophenotypic lymphocyte subpopulations comprising:
a solution comprising from about 10 mM to about 20 mM acetate buffer and about 0.075 percent by volume of formaldehyde, wherein said solution has a pH of from about 5.5 to about 7.5; and a composition comprising about 0.5 gm ammonium chloride, about 0.1 gm potassium bicarbonate, and about 10 mg of saponin per 100 ml of said buffer solution.
28. A diagnostic kit useful for the determination of nucleated erythrocytes comprising:
the multipurpose reagent system as recited in claim 20, and a solution of nuclear stain.
29. A diagnostic kit useful for lymphocyte immunophenotyping comprising:
the multipurpose reagent system as recited in claim 20, and a fluorochrome-conjugated antibody directed to a lymphocyte cell surface antigen.
30. A method for the rapid analysis of nucleated peripheral blood cells from a whole blood comprising the steps of:
forming a mixture by mixing whole blood and a multi-purpose reagent system in the ratio of about 1 part to a range of from about 16 to about 100 parts, wherein said reagent system comprises from about 3 to about 7 gm/L of a non-quaternary ammonium salt, from about 0.04 to about 0.1 percent by volume of a short chain aliphatic aldehyde, from about 10 to about 20 mM of a non-phosphate buffer, said non-phosphate buffer being characterized as substantially inert to said aliphatic aldehyde, and water, such that said multi-purpose reagent system is maintained at a pH between about 5.5 to about 7.5 and an osmolality between about 160 to about 310 mOsm per liter;
incubating the mixture at temperatures from about 25°C to about 46°C for at least about 10 seconds; and determining the nucleated peripheral blood cells with an automated electro-optical hematology instrumentation.
31. The method as recited in claim 30, further comprising the step of adding antibodies to the whole blood sample that are directed against cell surface markers.
32. The method as recited in claim 31, wherein said antibodies are fluorochrome-conjugated.
33. The method as recited in claim 31, wherein said antibodies comprise monoclonal antibodies.
34. The method as recited in claim 31, wherein said antibodies are directed to lymphocyte surface antigens.
35. The method as recited in claim 30, wherein the determination of nucleated peripheral blood cells comprises lymphocyte immunophenotyping.
36. The method as recited in claim 30, wherein the determination of nucleated peripheral blood cells comprises the determination of at least five classes of leukocytes.
37. The method as recited in claim 30, wherein the determination of nucleated peripheral blood cells comprises the determination of nucleated erythrocytes.
CA002156752A 1993-02-25 1994-02-03 Multipurpose reagent system for rapid lysis of whole blood samples Expired - Fee Related CA2156752C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2304293A 1993-02-25 1993-02-25
US08/023,042 1993-02-25

Publications (2)

Publication Number Publication Date
CA2156752A1 CA2156752A1 (en) 1994-09-01
CA2156752C true CA2156752C (en) 1999-01-05

Family

ID=21812791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002156752A Expired - Fee Related CA2156752C (en) 1993-02-25 1994-02-03 Multipurpose reagent system for rapid lysis of whole blood samples

Country Status (8)

Country Link
US (2) US5648225A (en)
EP (1) EP0685994B1 (en)
JP (1) JP2716267B2 (en)
AU (1) AU6235994A (en)
CA (1) CA2156752C (en)
DE (1) DE69434942T2 (en)
ES (1) ES2284160T3 (en)
WO (1) WO1994018828A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509192B1 (en) * 1992-02-24 2003-01-21 Coulter International Corp. Quality control method
US5879900A (en) * 1994-12-15 1999-03-09 Abbott Laboratories Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differentials
US5559037A (en) * 1994-12-15 1996-09-24 Abbott Laboratories Method for rapid and simultaneous analysis of nucleated red blood cells
US5882933A (en) * 1995-06-08 1999-03-16 Coulter International Corp. Method for determination of leukocytes and hemoglobin concentration in blood
FR2735578B1 (en) * 1995-06-13 1997-09-05 Hycel Groupe Lisabio ERYTHROCYTE LYSIS REAGENT, AND USE THEREOF IN LEUKOCYTE ISOLATION AND DISCRIMINATION PROCESSES
ATE472725T1 (en) * 1995-12-15 2010-07-15 Abbott Lab METHOD FOR SIMULTANEOUS ANALYSIS OF CELL VIABILITY, NUCLATED RED BLOOD CELLS AND LEUKOCYTE DIFFERENTIAL
TW379284B (en) * 1996-04-12 2000-01-11 Toa Medical Electronics Agent for detecting reticulocyte
US5858790A (en) * 1996-06-26 1999-01-12 Abbott Laboratories Hematology reference control and method of preparation
US5811303A (en) * 1997-04-01 1998-09-22 Streck Laboratories, Inc. Quantitative buffy coat control composition
US5917584A (en) * 1997-11-21 1999-06-29 Coulter International Corp. Method for differentiation of nucleated red blood cells
US5874310A (en) * 1997-11-21 1999-02-23 Coulter International Corp. Method for differentiation of nucleated red blood cells
US5874311A (en) * 1997-11-21 1999-02-23 Coulter International Corp. Method for differentiation of reticulocytes in blood
US6911313B2 (en) * 1998-02-06 2005-06-28 Sysmex Corporation Process for discriminating and counting erythroblasts
FR2778413B1 (en) * 1998-05-07 2000-08-04 Immunotech Sa NOVEL REAGENTS AND METHOD FOR LYSIS OF ERYTHROCYTES
FR2782730B1 (en) * 1998-08-25 2002-05-17 Biocom Sa CELL SEPARATION PROCESS FOR THE ISOLATION OF PATHOGENIC CELLS, PARTICULARLY RARE CANCERES, EQUIPMENT AND REAGENT FOR IMPLEMENTING THE PROCESS AND APPLICATION OF THE PROCESS
US6423505B1 (en) * 1998-12-03 2002-07-23 Becton Dickinson And Company Methods and reagents for quantitation of HLA-DR and CD11b expression on peripheral blood cells
US6200766B1 (en) 1998-12-03 2001-03-13 Becton Dickinson And Company Methods and reagents for quantitation of HLA-DR expression on peripheral blood cells
FR2813891B1 (en) * 2000-09-14 2005-01-14 Immunotech Sa MULTIFUNCTIONAL REAGENT FOR ERYTHROCYTES INVOLVING CARBAMATES AND APPLICATIONS
US7049093B2 (en) * 2000-11-08 2006-05-23 Sysmex Corporation Method of classifying and counting nucleated bone marrow cells
US20020068280A1 (en) * 2000-12-06 2002-06-06 Jeff Fairman Compositions and methods for DNA purification from whole blood
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
FR2821428B1 (en) * 2001-02-23 2004-08-06 Abx Sa REAGENT AND METHOD FOR THE IDENTIFICATION AND COUNTING OF BIOLOGICAL CELLS
US6448085B1 (en) * 2001-04-13 2002-09-10 Sysmex Corporation Quality control material and calibrator for nucleated red blood cell tested on hematology analyzer
US6573102B2 (en) 2001-07-27 2003-06-03 Coulter International Corp. Lytic reagent composition for determination of nucleated blood cells
US6472215B1 (en) * 2001-07-27 2002-10-29 Coulter International Corp. Method of analyzing nucleated red blood cells in a blood sample
US6916658B2 (en) * 2001-07-27 2005-07-12 Beckman Coulter, Inc. Method for measurement of immature granulocytes
JP2005506525A (en) * 2001-07-27 2005-03-03 ベックマン コールター，インコーポレーテッド Methods for measuring nucleated red blood cells
US6410330B1 (en) 2001-07-27 2002-06-25 Coulter International Corp. Method for measurement of nucleated red blood cells
AU2002323222A1 (en) * 2001-08-16 2003-03-03 Litron Laboratories Ltd Method for the enumeration of mammalian micronucleated erythrocyte populations with a single-laser flow cytometer
JP2005502863A (en) * 2001-08-23 2005-01-27 イムニベスト・コーポレイション Analysis of circulating tumor cells, fragments and debris
JP4227019B2 (en) * 2001-10-23 2009-02-18 デンカ生研株式会社 Method for separating blood cells and bacteria in blood and method for detecting bacteria in blood
US6913932B2 (en) * 2002-08-23 2005-07-05 Beckman Coulter, Inc. Formaldehyde-ammonium salt complexes for the stabilization of blood cells
US7247484B2 (en) * 2002-11-01 2007-07-24 Streck, Inc. Hematology reagent and methods
JP4371755B2 (en) * 2003-09-26 2009-11-25 シスメックス株式会社 B lymphocyte classification method
WO2005036164A1 (en) * 2003-10-02 2005-04-21 Beckman Coulter, Inc. Reference control for optical measurement of nucleated red blood cells of a blood sample
US7198953B2 (en) * 2003-10-12 2007-04-03 Beckman Coulter, Inc. Method of using a reference control composition for measurement of nucleated red blood cells
FR2862387B1 (en) * 2003-11-18 2006-06-09 C2 Diagnostics SYRINGE BLOCK FOR A LIQUID ANALYSIS AUTOMATE, IN PARTICULAR FOR BLOOD ANALYSIS
US7195919B2 (en) * 2003-12-19 2007-03-27 Beckman Coulter, Inc. Hematology controls for reticulocytes and nucleated red blood cells
US7208319B2 (en) * 2004-02-10 2007-04-24 Beckman Coulter, Inc. Method of measurement of nucleated red blood cells
EP1714146B1 (en) * 2004-02-10 2022-08-03 Beckman Coulter, Inc. Method of measurement of nucleated red blood cells
US7625712B2 (en) * 2004-05-21 2009-12-01 Beckman Coulter, Inc. Method for a fully automated monoclonal antibody-based extended differential
US7674598B2 (en) * 2004-05-21 2010-03-09 Beckman Coulter, Inc. Method for a fully automated monoclonal antibody-based extended differential
US7541190B2 (en) * 2005-02-07 2009-06-02 Beckman Coulter, Inc. Method of measurement of cellular hemoglobin
SE528697C2 (en) * 2005-03-11 2007-01-30 Hemocue Ab Volumetric determination of the number of white blood cells in a blood sample
DE102005013261A1 (en) * 2005-03-22 2006-09-28 Adnagen Ag Reagent and method for preventing time-dependent expression in biological cells
US7754487B2 (en) * 2006-11-14 2010-07-13 Beckman Coulter, Inc. Hematology linearity control composition, system and method of use
US7674622B2 (en) * 2006-12-22 2010-03-09 Abbott Laboratories, Inc. Method for determination of nucleated red blood cells and leukocytes in a whole blood sample in an automated hematology analyzer
CN101311725B (en) * 2007-05-25 2014-03-26 深圳迈瑞生物医疗电子股份有限公司 WBC differential count quality control matter and method for making same
US7816135B2 (en) 2007-07-05 2010-10-19 Becton, Dickinson And Company Method of analyzing lymphocytes
CN101349644B (en) * 2007-07-20 2012-06-27 深圳迈瑞生物医疗电子股份有限公司 Leukocytes classification agent and use method thereof
US8102161B2 (en) * 2007-09-25 2012-01-24 Tdk Corporation Stable output in a switching power supply by smoothing the output of the secondary coil
WO2009058876A1 (en) * 2007-10-29 2009-05-07 Beckman Coulter, Inc. Method for a rapid antibody-based analysis of platelet populations
CN101464454B (en) * 2007-12-18 2016-08-03 深圳迈瑞生物医疗电子股份有限公司 Leucocyte classification reagent and method
CN105440725A (en) * 2008-01-04 2016-03-30 深圳迈瑞生物医疗电子股份有限公司 Asymmetric cyanine fluorescent dye, composition and application in biological sample dyeing
CN101602762B (en) * 2008-06-10 2013-10-16 深圳迈瑞生物医疗电子股份有限公司 Asymmetric cyanine compound, preparation method and application thereof
US8148101B2 (en) * 2008-07-22 2012-04-03 Abbott Laboratories Method for classifying and counting bacteria in body fluids
CN101726579B (en) * 2008-10-17 2014-06-18 深圳迈瑞生物医疗电子股份有限公司 Blood test reagent and method
CN101723874B (en) * 2008-10-31 2013-09-11 深圳迈瑞生物医疗电子股份有限公司 Cyanine compound and application thereof in dyeing biological samples
CN101750476B (en) * 2008-12-08 2015-06-03 深圳迈瑞生物医疗电子股份有限公司 Blood analysis reagent and use method thereof
US8367358B2 (en) * 2008-12-17 2013-02-05 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Reagent, kit and method for differentiating and counting leukocytes
CA2759392A1 (en) 2009-04-27 2010-11-04 Abbott Laboratories Method for discriminating red blood cells from white blood cells by using forward scattering from a laser in an automated hematology analyzer
CN101988082B (en) * 2009-07-31 2015-04-08 深圳迈瑞生物医疗电子股份有限公司 Leukocyte classified counting reagent, kit and preparation method thereof and method of leukocyte classified counting
US9097704B2 (en) 2010-05-05 2015-08-04 Abbott Laboratories Method for hematology analysis
WO2011143044A2 (en) * 2010-05-10 2011-11-17 Idexx Laboratories, Inc. A lytic reagent system for flow cytometric analysis of leukocytes based on morphology or immunophenotypes
EP3104177B1 (en) * 2011-12-21 2020-11-25 Beckman Coulter, Inc. Method for labeling intracellular and extracellular targets of leukocytes
JP6124417B2 (en) 2012-05-31 2017-05-10 学校法人近畿大学 Preventive and / or therapeutic agent for peripheral neuropathic pain caused by anticancer agents
US9096885B2 (en) * 2012-07-05 2015-08-04 Beckman Coulter, Inc. Method and apparatus for determining white blood cell counts
JP6228085B2 (en) 2014-08-27 2017-11-08 シスメックス株式会社 Sample analyzer and sample analysis method
WO2016106688A1 (en) * 2014-12-31 2016-07-07 深圳迈瑞生物医疗电子股份有限公司 Nucleated red blood cell warning method and device, and flow cytometer
EP3344643A4 (en) 2015-09-04 2019-05-01 Qiagen Sciences LLC Methods for co-isolation of nucelic acids and proteins
JP6937116B2 (en) * 2016-12-15 2021-09-22 シスメックス株式会社 Pretreatment device and pretreatment method
JP2021514653A (en) * 2018-03-02 2021-06-17 セルックス・ダイアグノスティクス・インコーポレイテッド Sample preparation for antimicrobial susceptibility testing
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
CN113218847A (en) * 2021-04-12 2021-08-06 武汉凯普瑞生物技术有限公司 Hemolytic agent for flow cytometry analysis and preparation method and application method thereof
CN116396932B (en) * 2023-06-07 2023-08-29 上海精翰生物科技有限公司 Blood cell pretreatment composition and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses
IT1179044B (en) * 1983-08-15 1987-09-16 Nils O Rosaen MECHANISM OF TREATMENT OF A FLUID
US4637986A (en) * 1983-08-22 1987-01-20 Ortho Diagnostic Systems, Inc. Flow cytometry lysing reagent with leukoprotective agent for producing a 3-part WBC count
JPS6073356A (en) * 1983-09-29 1985-04-25 Toa Medical Electronics Co Ltd Reagent for blood analysis
US4902613A (en) * 1984-05-14 1990-02-20 Becton, Dickinson And Company Lysing agent for analysis of peripheral blood cells
US4654312A (en) * 1984-05-14 1987-03-31 Becton, Dickinson And Company Lysing agent for analysis of peripheral blood cells
US5188935A (en) * 1984-05-31 1993-02-23 Coulter Electronics, Inc. Reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes
US4751179A (en) * 1984-05-31 1988-06-14 Coulter Electronics, Inc. Method and reagents for differential determination of four populations of leukocytes in blood
JPS61280565A (en) * 1985-06-06 1986-12-11 Toa Medical Electronics Co Ltd Reagent for measuring reticulocyte for flow sightmetry
US4745071A (en) * 1985-09-05 1988-05-17 Sequoia-Turner Corporation Method for the volumetric differentiation of blood cells types
US4978624A (en) * 1985-09-06 1990-12-18 Technicon Instruments Corporation Reagent for the determination of a differential white blood cell count
US4801549A (en) * 1985-09-06 1989-01-31 Technicon Instruments Corporation Method for the determination of a differential white blood cell count
US5141855A (en) * 1986-07-28 1992-08-25 Eastman Kodak Company Signal amplifying cobalt (III) redox reagents and methods for the determination of analytes in aqueous fluids
KR970007077B1 (en) * 1987-03-13 1997-05-02 코울터 일렉트로닉스 인커퍼레이티드 Multi-part diefferential analyzing apparatus using light scatter techniques
US5155044A (en) * 1987-03-13 1992-10-13 Coulter Electronics, Inc. Lysing reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples
JP2935529B2 (en) * 1990-03-01 1999-08-16 シスメックス株式会社 Leukocyte classification method and reagent
JPH0746102B2 (en) * 1987-07-31 1995-05-17 東亜医用電子株式会社 Reticulocyte assay reagent for flow cytometry
US5057413A (en) * 1988-06-13 1991-10-15 Becton, Dickinson And Company Method for discriminating between intact and damaged cells in a sample
US5047321A (en) * 1988-06-15 1991-09-10 Becton Dickinson & Co. Method for analysis of cellular components of a fluid
US5098849A (en) * 1988-07-13 1992-03-24 Becton Dickinson And Company Material and method to reduce non-specific binding of a labelled material
FR2654744B1 (en) * 1989-11-20 1992-03-13 Abx Sa REAGENT AND METHOD OF USING SAME FOR THE AUTOMATIC DETERMINATION IN FLOW CYTOMETRY OF AT LEAST ONE LEUKOCYTAIC SUB-POPULATION FROM TOTAL BLOOD.
JP2927979B2 (en) * 1991-02-22 1999-07-28 シスメックス株式会社 Classification of erythroblasts by flow cytometry
WO1992019966A1 (en) * 1991-05-09 1992-11-12 Streck Laboratories, Inc. White blood cell hematology control
US5262329A (en) * 1991-06-13 1993-11-16 Carver Jr Edward L Method for improved multiple species blood analysis

Also Published As

Publication number Publication date
EP0685994B1 (en) 2007-03-21
WO1994018828A1 (en) 1994-09-01
CA2156752A1 (en) 1994-09-01
EP0685994A1 (en) 1995-12-13
ES2284160T3 (en) 2007-11-01
US5516695A (en) 1996-05-14
EP0685994A4 (en) 2001-10-31
JPH08507147A (en) 1996-07-30
US5648225A (en) 1997-07-15
JP2716267B2 (en) 1998-02-18
AU6235994A (en) 1994-09-14
DE69434942T2 (en) 2007-11-29
DE69434942D1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
CA2156752C (en) Multipurpose reagent system for rapid lysis of whole blood samples
EP1021701B1 (en) Hematology reference control and method of preparation
US7625712B2 (en) Method for a fully automated monoclonal antibody-based extended differential
AU669692B2 (en) Suspension media for hematological composition and method for its use
US5786224A (en) Reagent and method for differential determination of leukocytes in blood
US6977156B2 (en) Flow cytometry reagent and system
CA2367780A1 (en) Single channel, single dilution detection method
EP1000355A1 (en) Method for determination of leukocytes and hemoglobin concentration in blood
AU606493B2 (en) Conservative whole blood sample preparation technique
JPH10503285A (en) Quality control method for hematological instruments
JP2005233935A (en) Hematological control of reticulocyte and nucleated red blood cell
Hübl et al. Measurement of absolute concentration and viability of CD34+ cells in cord blood and cord blood products using fluorescent beads and cyanine nucleic acid dyes
Hendriks et al. Flow cytometric method for the routine follow‐up of red cell populations after bone marrow transplantation
Fibach et al. Changes in ABH antigen expression on red cells during in vivo aging: a flow cytometric analysis
GEE Preparation of samples for flow cytometric analysis
EP0685071A1 (en) Method for absolute counting of rare cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140204